Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -25.13
- Piotroski Score 1.00
- Grade Buy
- Symbol (IKT)
- Company Inhibikase Therapeutics, Inc.
- Price $2.30
- Changes Percentage (14.36%)
- Change $0.29
- Day Low $1.96
- Day High $2.39
- Year High $3.82
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $6.50
- High Stock Price Target $8.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.32
- Trailing P/E Ratio -0.51
- Forward P/E Ratio -0.51
- P/E Growth -0.51
- Net Income $-19,028,883
Income Statement
Quarterly
Annual
Latest News of IKT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Triller is hiring TikTok's former head of product to run its video app, as its other CEO hire falls through
Triller recently appointed former TikTok executive Sean Kim as CEO of its video app, aiming to strengthen its position in the competitive landscape. As the company plans for future growth, it faces le...
By Business Insider | 1 day ago -
Senator says Trump cannot ignore law requiring ByteDance to divest TikTok by next year
Senator Blumenthal emphasized that President-elect Trump must comply with the law mandating Chinese-owned TikTok to divest by January unless President Biden grants an extension. Blumenthal stressed th...
By Yahoo! Finance | 3 days ago -
Pennsylvania aesthetician and teen warn skin care products from TikTok can cause damage, breakouts
TikTok is a major platform for skincare products and advice, popular among teenagers. However, caution is advised as products may cause adverse reactions. Experts warn of potential side effects and em...
By CBS News | 3 days ago
